Optiver Holding
FULC icon

Optiver Holding’s Fulcrum Therapeutics FULC Stock Holding History

Optiver Holding’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.07K Buy
530
+208
+65% +$1.93K ﹤0.01% 1516
2025
Q4 		$3.64K Hold
322
– – ﹤0.01% 1602
2025
Q3 		$2.96K Buy
+322
New +$2.33K ﹤0.01% 2192

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Optiver Holding's FULC Position: Q1 2026 in Review

Optiver Holding increased its Fulcrum Therapeutics (FULC) stake by 65% in Q1 2026, buying an estimated $1.93K and bringing the position to 530 shares worth $4.07K. The position accounts for ﹤0.01% of the portfolio, ranked #1516.

Optiver Holding first reported a position in FULC in Q3 2025 and has held it in 3 quarters since. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Optiver Holding held 530 shares of Fulcrum Therapeutics worth $4.07K as of Q1 2026.
  • Optiver Holding bought 208 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.93K.
  • Fulcrum Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1516 holding.
  • Optiver Holding first reported a position in Fulcrum Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.